This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 100 entries.
Superbugs were this week labelled as “the next great health crisis of our time” and there are a few ASX stocks seeking to address it. Superbugs are bacteria, viruses, fungi and parasites immune to conventional antibiotics and pharmaceuticals. Yesterday, on the eve of World Antimicrobial Resistance Awareness Week, Monash University has warned superbugs could kill […]
“Is this just a projection…?” The narrator of this video asks, as she examines the possibility of a world devoid of effective antibiotics, a most precious resource. Due to “use, misuse, overuse” of antibiotics, a dire future is forecast. It is thought provoking, unnerving – but also deeply motivating to be part of global action […]
AusBiotech’s BiotechDispatch featured our BTX 1801 antimicrobial program update today. Read the full article here.
The Australian Government Department of Health has this week published a summary of funding and strategy measures announced to address antimicrobial resistance (AMR) in the recent 2020-21 Federal Budget. This includes $22.5m to address the priorities identified in Australia’s National Antimicrobial Resistance Strategy – 2020 & Beyond. Key areas, as quoted in this excerpt, include: […]
Botanix Pharmaceuticals (BOT) has completed a pre-investigational new drug meeting with the U.S. Food and Drug Administration’s (FDA) Office of Infectious Diseases. The meeting assessed the potential of initiating clinical development of the company’s BTX 1801 antimicrobial drug for preventing surgical site infections (SSIs) in the U.S. It also enabled the company to receive feedback […]
The Green Fund has published a summary of Botanix Pharmaceutical’s BTX 1801 announcement today, an update on the development pathway for our BTX 1801 antimicrobial product. Take a look at the article here.
Botanix (ASX:BOT) has today announced it has secured a clear development path from the FDA for its BTX 1801 synthetic cannabidiol antimicrobial product, following the successful completion of a Pre-Investigational New Drug (Pre-IND) meeting. Our team will have more clinical data to share soon too – our BTX 1801 Phase 2a study in Perth is […]
The Motley Fool’s Aaron Teboneras featured Botanix Pharmaceuticals as a top stock pick in an article today. “At the time of writing, the Botanix share price is trading at 10 cents, up 7.5% for the day. With a market capitalisation of $97 million, if the company can perform to market expectations, its share price will […]
Two US lawmakers have introduced a bipartisan bill to create a new payment model to encourage drug developers to develop new classes of antibiotics. It’s called the PASTEUR Act, which will facilitate upfront payments to companies in exchange for unlimited access to their antibiotics. In turn, drug makers can recover their costs and turn a […]
Botanix Pharmaceuticals Executive Director, Matt Callahan, spoke with Stockhead about the global threat of antimicrobial resistance yesterday: “The alarm bells have been going off the last five years (on antimicrobial resistance), but no one’s really believed that the global economy could be stopped and millions and millions of deaths could be caused by some kind […]
AUSTRALIA
D2, 661 Newcastle Street, Leederville WA 6007
USA
3602 Horizon Drive, Suite 160, King of Prussia, PA 19406
Be notified of important news from Botanix.
AU +61 8 6555 2945
US + 1 445 300 3403
info@botanixpharma.com